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Introduction
There is not yet any clinically established method for following
local biochemical parameters in organs when they are
affected by hypoxia or ischemia, or are developing organ
failure. In the experimental setting it is possible to follow
metabolic parameters such as glucose, lactate, pyruvate and
glycerol using microdialysis equipment [1,2]. In the clinical
setting, thus far microdialysis has mostly been used in studies
of subcutaneous adipose tissue [3], muscle [4] and human
brain [5–8].
In intensive care medicine, diagnostic and therapeutic
decisions are frequently based on measuring blood
concentrations of indicator substances, but it is well known
that biochemical reactions take place in the tissues. It has
therefore been suggested that measurement of tissue
chemistry reveals more valuable data than does analysis of
systemic parameters in the blood [9]. Furthermore, in the
past, detection of tissue concentrations of a substance of
interest was hindered by the requirement for tissue harvesting
[10], but harvesting is not necessary with microdialysis.
This article reviews the technique of microdialysis and its
development from ‘bench to bedside’ for use in clinical
research, major surgical interventions and critical care. We also
discuss whether biochemical tissue monitoring has the
potential to surpass blood analysis and become the standard
technique for certain clinical procedures. Because fundamental
research in numerous studies and reviews of the value of
biochemical monitoring in the field of neurosurgery have been
published, here we focus on the use of microdialysis in general
perioperative and intensive care treatment.
Microdialysis
Microdialysis was introduced by Ungerstedt and Pycock [11]
and was used primarily in brain research, but it is now
increasingly being applied to various tissues in experimental
studies dealing with critical illness, and has some applica-
tions in the clinical setting [1,2,9]. In theory, the microdialysis
catheter acts like a blood capillary [12]. Thereby, it is
proposed that microdialysis provides information regarding
events that take place in the tissue before any chemical
events are reflected by changes in systemic blood levels of
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Abstract
Microdialysis is a technique used to measure the concentrations of various compounds in the
extracellular fluid of an organ or in a body fluid. It is a form of metabolic monitoring that provides real-
time, continuous information on pathophysiological processes in target organs. It was introduced in the
early 1970s, mainly to measure concentrations of neurotransmitters in animal experiments and clinical
settings. Using commercial equipment it is now possible to conduct analyses at the bedside by
collecting interstitial fluid for measurement of carbohydrate and lipid metabolites. Important research
has been reported in the field of neurosurgery in recent decades, but use of metabolic monitoring in
critical care medicine is not yet routine. The present review provides an overview of findings from
clinical studies using microdialysis in critical care medicine, focusing on possible indications for clinical
biochemical monitoring. An important message from the review is that sequential and tissue-specific
metabolic monitoring, in vivo, is now available.
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indicator substances [13]. Briefly, for those who are less
familiar with the technique, the capillaries and the
semipermeable membrane are surrounded by substrates and
metabolites in the extracellular fluid of the tissue (Fig. 1).
These molecules diffuse across the membrane part of the
catheter and equilibrate with the perfusion fluid, which is
pumped through the probe at very low rates of flow. Changes
in the concentration of a substrate in the surrounding milieu
are reflected by subsequent changes in the dialysate [14].
Rather than inserting an instrument into the tissue,
microdialysate is extracted and later analyzed in the
laboratory or clinically at the patient’s bedside.
Clinical application of microdialysis was ‘catalyzed’ by the
development of commercially available microdialysis catheters
that may be used in humans [9]. Because of modern technical
innovations, it is now possible to determine dialysate and
tissue concentrations immediately at the bedside during
intensive care treatment [15]. The first reported application of
microdialysis in humans was a study of interstitial glucose,
which was published in 1987 [16]. Since then, microdialysis
has been investigated in various human tissues, for example in
cancer research [9] and pharmaceutical studies [17,18], and
in clinical research [19]. However, particular interest is
currently devoted to perioperative biochemical monitoring in
the fields of vascular, gastrointestinal and heart surgery, and
postoperative observation.
Clinical applications
Microdialysis in vascular surgery
Several studies dealing with tissue vulnerability during
ischemia and reperfusion have been reported [20,21].
Previous studies on the consequences of ischemia in skeletal
muscle usually involved venous blood sampling or tissue
biopsies, but microdialysis has the advantage that metabolite
levels can be monitored directly in the interstitial fluid of the
tissue, even when blood flow is restricted. Lundberg and
coworkers [22] used microdialysis to grade the severity of
peripheral vessel disease. Responses of interstitial muscle
concentrations of lactate and the lactate–pyruvate ratio to
blood flow reduction were variable, whereas glucose
concentration subsequently fell. Using microdialysis, Metzsch
and coworkers [23] investigated metabolic changes during
open and endovascular aortic surgery, and found that stent
procedures had a lesser impact on regional tissue
metabolism over 24 hours than did open aortic procedures.
In the field of orthopedic surgery, Korth and coworkers [24]
demonstrated that interstitial concentrations of glucose,
lactate, and hypoxanthine – indicators of tissue ischemia –
change more markedly after exsanguination of the extremity
than after circulatory occlusion alone. The energy status in
muscle tissue was immediately visible after induction of
ischemia, when glucose levels decreased and the extracellular
concentrations of lactate and hypoxanthine increased.
Our study group clinically monitored patients during
abdominal aortic surgery using microdialysis of the sub-
cutaneous tissue. We found the glucose–lactate ratio to be
the most sensitive marker for detection of ischemic events
(Fig. 2 [25]); in another study we focused on the lactate–
pyruvate ratio and interstitial glycerol [26].
Monitoring in the neonatal intensive care unit
Microdialysis in the neonatal intensive care unit is a new
approach to continuous monitoring of newborn patients who
are at risk from hypoglycemia (a commonly encountered
problem in neonatal intensive care). The objective of the
study conducted by Baumeister and coworkers [27] was to
evaluate subcutaneous microdialysis in long-term glucose
monitoring in the neonatal intensive care unit. By using
subcutaneous microdialysis, blood draws and painful stress
resulting from diagnostic blood sampling in high-risk
neonates were reduced. Subcutaneous microdialysis has
been used continuously for up to 4 days in neonates during
intensive care, and for 3 and 7 days in adult insulin-
dependent diabetic patients [19]. In their clinical study,
Baumeister and coworkers [27] continued metabolic
monitoring for 4–16 days and found a close correlation
(r ~ 0.97) between blood and interstitial glucose levels.
Monitoring the gastrointestinal tract in the intensive
care unit
Ensuring adequacy of visceral circulation is of high priority in
critical illness. However, no clinical instrument has yet been
developed to continuously monitor biochemical and circulatory
parameters  in this compartment [28,29]. Decrease in
intestinal blood flow or derangement of visceral oxygen supply
is well known to induce local and systemic inflammation. This
Figure 1
Principle of microdialysis. The microdialysis probe is inserted into the
tissue where substances in the extracellular fluid surround the
semipermeable membrane at the tip of the catheter. Following
equilibration of the tissue metabolites with the perfusion fluid, the
dialysate can be analyzed for concentrations of products of energy
metabolism (glucose, lactate, pyruvate) as indicators of hypoxia and
ischemia. In addition, interstitial glycerol can be determined, which is a
parameter of lipolysis and/or cell membrane damage.365
could subsequently be responsible for multiple organ
dysfunction and/or failure [30]. Many investigators have
attempted to measure adequacy of splanchnic circulation either
by measuring splanchnic blood flow in global splanchnic
blood flow or local tissue perfusion or by evaluating
metabolism in one region of the gastrointestinal tissue [28].
However, Tenhunen and coworkers have forwarded a theory,
supported by several studies conducted in various experi-
mental and clinical settings [31–36], that changes in tissue
perfusion and metabolism in response to different drug
interventions vary. That research group is by far the most
experienced with respect to experimental biochemical
monitoring of the gastrointestinal tract in the critical care
setting. They identified intestinal histamine release in a
selective regional intestinal ischemia–reperfusion model, not
during ischemia but only during the reperfusion phase [33].
Following short-term endotoxin challenge, Oldner and
coworkers [37] observed early increases in microdialysate
lactate and hypoxanthine in ileum, as opposed to systemically
detectable changes. However, insertion of a microdialysis
probe into the intestinal wall is not feasible for clinical
application. Subsequently, intraluminal [34] and intra-
peritoneal [38] applications were evaluated in experimental
ischemia and hypoxia. Using microdialysis, Ungerstedt and
colleagues [39] investigated local and regional gastro-
intestinal ischemia caused by vascular occlusion. Also in the
setting of gastrointestinal ischemia caused by vascular
occlusion, Jansson and coworkers [40] were the first to apply
intraperitoneal microdialysis in clinical pilot studies of patients
undergoing abdominal surgery. Intraperitoneal microdialysis
appears to represent a very promising clinical tool for
continuous monitoring of metabolic status in visceral tissues.
It is minimally invasive; for example, the probe may be left in
situ after laparotomy.
Liver monitoring in the intensive care unit
Despite improvements in liver preservation and surgery, a
significant incidence of graft dysfunction following liver
transplantation persists. Microdialysis offers the possibility to
monitor the liver during and after transplantation. Nowak and
coworkers, who are pioneers in this field, investigated this
application both experimentally [41] and clinically [42]. In
their studies they investigated ischemia–reperfusion injury
and post-transplant vascular complications, with apparent
impact on hepatic metabolism, using microdialysis. They
characterized the course of normalization in biochemical
markers during the 72-hour postoperative period following
liver transplantation. Nowak and coworkers concluded that
the procedure is easy to perform and safe for the patient.
They stated that the detection of specific pathologic changes
(e.g. arterial and portal vein thrombosis, early graft rejection)
might be possible using microdialysis, and that this should be
addressed in further studies.
Monitoring sepsis
Increasing interest has been devoted to metabolic changes that
occur in the tissue during sepsis and endotoxemia. In their
animal experiments, Tenhunen and coworkers [36] induced a
biphasic endotoxic shock lasting 12 hours and measured
regional blood flows. Endotoxin shock per se had
heterogeneous effects on tissue perfusion, and it was observed
that blood flow changes did not correlate with metabolic events.
We performed endotoxin [43] and monophosphoryl-lipid A [44]
vaccination before induction of endotoxemia in animal
experiments. Despite nonsignificant differences in hemodynamic
parameters, lower interstitial lactate and glycerol accumulation
(Fig. 3) were clearly associated with prolonged survival.
Stjernstrom and coworkers [15] were the first to report on the
use of microdialysis in sepsis; they described case reports of
microdialysis monitoring in patients with septic shock.
Clinically, Martinez and coworkers [45] evaluated adipose
tissue metabolism in severely ill patients. The aim of the latter
investigation was to study whole body substrate utilization
and adipose tissue lactate and glycerol release in healthy
human volunteers and in two groups of critically ill patients:
one group of patients with severe sepsis or septic shock and
another with circulatory failure after cardiac surgery. Differ-
ences in tissue metabolic response were found between
sepsis/septic shock and cardiac failure patients using micro-
dialysis. The observations summarized above, along with
Fink’s theory of ‘cytopathic hypoxia’ [46] in septic states, add
weight to a recommendation to introduce biochemical tissue
monitoring into critical care practice.
Monitoring pharmacological concentrations
Achievement of appropriate concentrations of antibiotics at
target sites is associated with clinical outcome [47] and
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Figure 2
Interstitial glucose/lactate ratio in the ischemic and nonischemic region
during abdominal aortic surgery. *P < 0.05.366
therefore is of particular importance. Recent data, however,
strongly suggest that concentrations of antibiotics reached in
the interstitium of soft tissues might be ineffective in critically
ill patients, despite achievement of adequate plasma
concentrations [18]. Fundamental experimental research in
the field of drug monitoring using microdialysis has been
reported [48]; this was recently reviewed by Joukhadar and
coworkers [17].
Monitoring myocardial metabolism
Several experimental approaches such as biochemical
analysis of coronary sinus blood, myocardial biopsy and
magnetic resonance imaging have been taken in order to
describe the metabolic changes that occur during and after
cardiopulmonary bypass [49]. With the exception of septic
conditions [46], the interstitial concentration of lactate has
been shown to be closely related to variations in tissue
perfusion [1] and may thus be used as a surrogate marker of
myocardial ischemia. Following experimental evaluation by
Kennergren and coworkers [49], Habicht and colleagues
[50] were the first to introduce this concept into the clinic by
inserting microdialysis probes into the interventricular septum
of the human heart. Kennergren and colleagues [51] then
focused on changes in troponin T and aspartate transferase
in patients undergoing coronary artery bypass grafting and
valve surgery.
We investigated the course of myocardial metabolism in
patients undergoing standard coronary artery bypass grafting
[52]. In contrast to blood levels, myocardial lactate–pyruvate
ratio exhibited marked changes during the period of
observation; pyruvate was found to be a promising indicator
of tissue reperfusion. In a recent study of myocardial
microdialysis (unpublished data), we categorized patients by
lactate concentration at baseline into a high lactate group
and a low lactate group. We found an association between
increased myocardial lactate levels – as determined by
microdialysis – and reduced myocardial performance with
difficult weaning from cardiopulmonary bypass during
coronary artery bypass grafting. This suggests that
myocardial microdialysis may be a useful adjunct for
stratifying treatment in these interventions (unpublished data).
Microdialysis may reveal promising diagnostic and
therapeutic options by permitting analysis of the effects of
different treatment strategies on myocardial metabolism (i.e.
the ‘target tissue’ of therapeutic interventions) in cardiac
surgical patients.
Conclusion
Microdialysis has been introduced into several sectors of
critical care medicine. The precise role and cost-effectiveness
of microdialysis, in comparison with well established
technologies, in developing strategies to improve organ
function in intensive care remain to be determined. However,
even in the well established field of neurosurgery, clinical use
of microdialysis has not yet been found to improve outcome.
Current data support a recommendation to introduce this new
technique to evaluate the adequacy of regional tissue
metabolism; it may even permit monitoring of the effects of
therapeutic interventions. Further studies of various
approaches are needed to conclude which seems clinically
most feasible, which is sufficiently non-invasive, and which
supplies the clinician with the most physiologically relevant
information. Whether clinicians will be able to monitor their
‘tissues of interest’ directly, with microdialysis playing a key
role, will be determined by the results of further evaluation.
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Figure 3
Interstitial muscle concentrations of (a) lactate and (b) glycerol during continuous endotoxin infusion with (black) or without (white) pretreatment
with monophosphoryl lipid A (MPL). *P < 0.05, between groups; #P < 0.05, versus baseline (only assessed at 150 and 300 min).367
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